← Leaderboards
Benjamin Titz
Cellectar Biosciences, Inc.
$2,292,085
Attributed
$2,292,085
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2015–16$2M$1.5M$1M$500K$0
'15
'16
Funding mix
By agency
NIH$2,292,085 · 1
By mechanism
N43$2,292,085 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Adjuvant”
- Lawrence Corey · Fred Hutchinson Cancer Center$377,142,999
- Norman Wolmark · Nsabp Foundation, Inc.$267,141,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$167,183,168
- David Heimbrook · Leidos Biomedical Research, Inc.$151,668,128
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$131,206,481
- Peter B. Gilbert · Fred Hutchinson Cancer Center$117,668,001
Research focus
AdjuvantBreast Cancer ModelBreast Cancer PatientChemical PropertyChemical ReactionChemistryClinically RelevantDose-LimitingDrug KineticsEffective TherapyI125 IsotopeInvestigationIn VivoMicrometastasisMouse ModelNeoadjuvant TherapyNeoplasm MetastasisNormal Tissue MorphologyOutcome ForecastPre-Clinical ModelRadiochemicalRadiometryRecurrenceToxic Effect